3 results match your criteria: "Eastern Piedmont University of Novara[Affiliation]"
The Integration of qSOFA with Clinical Variables and Serum Biomarkers Improves the Prognostic Value of qSOFA Alone in Patients with Suspected or Confirmed Sepsis at ED Admission.
J Clin Med
April 2020
Unit of Internal Medicine, Clinica Medica, Department of Medical Surgical and Health Sciences-University of Trieste, Strada di Fiume 447, 34100 Trieste, Italy.
Article Synopsis
- The study critiques the existing qSOFA tool for predicting mortality in sepsis patients outside intensive care units and aims to enhance its effectiveness.
- Researchers developed three new predictive models by combining qSOFA with clinical variables and serum biomarkers from 848 undifferentiated patients and 545 diagnosed with sepsis.
- The new models, especially eqSOFA1 and eqSOFA2+CRP+MR-proADM, showed significantly better predictive ability than qSOFA in identifying mortality risk, proving useful in both initial and validation patient groups.
Stem cell treatment in Amyotrophic Lateral Sclerosis.
J Neurol Sci
February 2008
Department of Neurology, Azienda Ospedaliera, Eastern Piedmont University of Novara, Novara, Italy.
Amyotrophic Lateral Sclerosis is a progressive fatal neurodegenerative disease that targets motor neurons. Its origin is unknown but a main role of reactive astrogliosis and microglia activation in the pathogenesis has been recently demonstrated. Surrounding neurons with healthy adjoining cells completely stops motor neuron death in some cases.
View Article and Find Full Text PDFAutologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis.
Neurol Res
July 2006
Department of Neurology, Eastern Piedmont University of Novara, Novara, Italy.
Objectives: Our study was aimed to evaluate the feasibility and safety of intraspinal cord implantation of autologous mesenchymal stem cells (MSCs) in a few well-monitored amyotrophic lateral sclerosis (ALS) patients.
Methods: Seven patients affected by definite ALS were enrolled in the study and two patients were treated for compassionate use and monitored for at least 3 years. Bone marrow was collected from the posterior iliac crest according to the standard procedure and MSCs were expanded ex vivo according to Pittenger's protocol.